Foundry Partners, LLC Akebia Therapeutics, Inc. Transaction History

Foundry Partners, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 23, 2020	SELL	$2.39 - $13.08 $154,183 - $843,816	-64,512 Closed	0 $0
Q2 2020 Aug 03, 2020	SELL	$6.67 - $13.58 $16,534 - $33,664	-2,479 Reduced 3.7%	64,512 $876,000
Q1 2020 May 08, 2020	SELL	$4.1 - $10.24 $96,936 - $242,104	-23,643 Reduced 26.09%	66,991 $508,000
Q4 2019 Feb 10, 2020	SELL	$3.16 - $6.73 $6,825 - $14,536	-2,160 Reduced 2.33%	90,634 $573,000
Q3 2019 Oct 23, 2019	SELL	$3.55 - $5.4 $773 - $1,177	-218 Reduced 0.23%	92,794 $364,000
Q2 2019 Jul 18, 2019	SELL	$4.1 - $8.05 $1,107 - $2,173	-270 Reduced 0.29%	93,012 $450,000
Q1 2019 Apr 22, 2019	BUY	$5.41 - $8.73 $87,057 - $140,483	16,092 Added 20.85%	93,282 $764,000
Q4 2018 Jan 10, 2019	BUY	$5.39 - $9.15 $700 - $1,189	130 Added 0.17%	77,190 $682,000
Q4 2018 Jan 10, 2019	SELL	$5.39 - $9.15 $700 - $1,189	-130 Reduced 0.17%	77,060 $426,000
Q3 2018 Oct 17, 2018	SELL	$7.44 - $10.65 $892 - $1,278	-120 Reduced 0.16%	77,190 $682,000
Q2 2018 Jul 19, 2018	BUY	$9.15 - $11.34 $206,506 - $255,932	22,569 Added 41.23%	77,310 $772,000
Q1 2018 May 16, 2018	BUY	$9.53 - $15.68 $521,681 - $858,338	54,741 New	54,741 $522,000

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $324M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Foundry Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Foundry Partners, LLC with notifications on news.